· · · · · · · · · · · · · · · · · · ·				-	ATTO DOCUMENTO				
		,	1	31	ATTY. DOCKET NO.			ATION NO.	;
EXAMINER DOCUMENT NUMBER DATE NAI AA1 AB1 AC1 AD1 AE1 EXAMINER DOCUMENT NUMBER DATE EXAMINER DOCUMENT NUMBER DATE EXAMINER DOCUMENT NUMBER DATE EXAMINER DOCUMENT NUMBER DATE OTHER (Inclu AG1 AJ1 OTHER (Inclu AK1 Byrne et al., "Glucagon-Like Per Subjects with Impaired Glucose Impaired Glucose Tolerance", Impaired Glucose Tolerance", Impaired Glucagon-Like Per Diabetic Medicine, Vol. 13, pp. AM1 Byrne & Göke, "Human Studies Diabetic Medicine, Vol. 13, pp.			7 2005 g	18528.543 / 0206-UTL-9 APPLICANTS		09/719,410			
INFC] DRMATIO	FORM PTO-1449	STATEMENT		Burkhard GÖKE et al.				
TRADEMARK					FILING DATE GROUP				
					December 12, 2000		1653		
	<u>.</u>		<u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>	Hel	PATENT DOCUMENTS		1033		
EXAMINER	T	DOCUMENT	T	0.3. 1	ATENI DOCUMENTS			SUB-	T
INITIAL			DATE	NAME			CLASS	CLASS	FILING DATE
	AA1			<u> </u>					
	AB1				······				
	AC1								
	AD1								
	AEl								
				FOREIG	N PATENT DOCUMENTS				
EXAMINER INITIAL			DATE	COUNTRY	<i>Y</i>		CLASS	SUB- CLASS	TRANSLATION
	AFI								Yes No
	AG1	<u> </u>							Yes No
	AH1				:	,			Yes
	AII								No Yes
 	AJI							-	No Yes
	<u> </u>	<u></u>	OTHER	(Including A	uthor Title Date Partinent P	laces etc.)		1	No No
	Γ	T		(Including A	author, Title, Date, Pertinent P	ages, etc.)			•
AN	AKI	Byrne et al., "Glucagon-Like Peptide-1 Improves the Ability of the β-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance", <u>Diabetes</u> , Vol. 46, Supplement (1), page 33A, Abstract 0127 (1997)							
Au	ALl	Byrne et al., "GLP-1 Improves First Phase Insulin Secretion without Altering Insulin Sensitivity in Subjects with Impaired Glucose Tolerance", <u>Diabetes</u> , Vol. 47, Supplement (1), page A192, Abstract 0744 (1998)							
AM	AM1	Byrne & Göke, "Human Studies with Glucagon-like-peptide-1: Potential of the Gut Hormone for Clinical Use", <u>Diabetic Medicine</u> , Vol. 13, pp. 854-860 (1996)							
AN	ANI	Wang et al., "Glucagon-like Peptide-1 Can Reverse the Age-related Decline in Glucose Tolerance in Rats", The Journal of Clinical Investigation, Vol. 99, No. 22, pp. 2883-2889 (1997)							
	AOI								`,
	AP1								,
EXAMINER							DATE CO	NSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not									
EXAMINER: In considered. Inclu	ntial if refo ide copy o	erence considered, f this form with ne	whether or not xt communicat	citation is in ion to Applic	conformance with MPEP 609 cant.	9. Draw line thro	ough citation	n if not in cor	formance and not

,	OTPE	À
		8
Ş	APR 1 1 2005	닖
ř		#
ГО-1449	STATEMENT	•
OSURE	STATEMENT	

ATTY. DOCKET NO.	APPLICATION NO.	
18528.543 / 0206-UTL-9	09/719,410	
APPLICANTS		
Burkhard GÖKE et al.	•	
FILING DATE	CROUP	

FORM P **INFORMATION DISCL** GKUUI December 12, 2000 1653 **U.S. PATENT DOCUMENTS** EXAMINER DOCUMENT SUB-INITIAL **NUMBER** DATE NAME **CLASS CLASS FILING DATE** AA1 ABI ACI ADI AE1 FOREIGN PATENT DOCUMENTS **EXAMINER** DOCUMENT SUB-INITIAL **NUMBER** DATE COUNTRY **CLASS CLASS** TRANSLATION Yes **AF1** No Yes AG1 No Yes AHI No Yes All No Yes AJI No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) D'ALESSIO et al., "Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons", The Journal of Clinical Investigation, Vol. 97, No. 1, pp. 133-138 (1996) ALI European Search Report published January 12, 2005 in European Patent Application No. 04075402.0 RITZEL er al., "A synthetic glucagon-like peptide-1 analog with improved plasma stability", Journal of AMI Endocrinology, Vol. 159, pp. 93-102 (1998) SCHIRRA et al., "Exendin(9-39) amide is an Antagonist of Glucagon-like Peptide-1(7-36) amide in Humans", J. ANI Clin. Invest., Vol. 101, No. 7, pp. 1421-1430 (1998) The crossed references have been considered on PTO-1449 submitted on or/22/05. fee Advisory action of 04/20/05 A01 API

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.